Robert Driscoll
Stock Analyst at Wedbush
(1.84)
# 3,076
Out of 4,869 analysts
161
Total ratings
28.87%
Success rate
-9.06%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert Driscoll
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KURA Kura Oncology | Reiterates: Outperform | $36 | $5.85 | +515.38% | 9 | Jun 20, 2025 | |
| ZNTL Zentalis Pharmaceuticals | Reiterates: Neutral | $4 | $1.30 | +208.88% | 11 | May 15, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Outperform | $8 → $6 | $1.19 | +404.20% | 3 | May 9, 2025 | |
| RVMD Revolution Medicines | Reiterates: Outperform | $67 | $39.66 | +68.94% | 5 | Apr 28, 2025 | |
| GLUE Monte Rosa Therapeutics | Maintains: Outperform | $15 → $17 | $4.63 | +267.17% | 4 | Mar 21, 2025 | |
| ARVN Arvinas | Downgrades: Neutral | $57 → $12 | $7.44 | +61.29% | 9 | Mar 12, 2025 | |
| DAWN Day One Biopharmaceuticals | Reiterates: Outperform | $32 | $6.32 | +406.33% | 6 | Feb 26, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Outperform | $52 | $21.69 | +139.74% | 9 | Dec 17, 2024 | |
| TYRA Tyra Biosciences | Reiterates: Outperform | $28 | $9.23 | +203.36% | 8 | Oct 25, 2024 | |
| BDTX Black Diamond Therapeutics | Reiterates: Outperform | $16 | $2.33 | +586.70% | 10 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $8.62 | +248.03% | 7 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $22 | $1.17 | +1,780.34% | 10 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $51 | $8.24 | +518.93% | 1 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $5 | $0.67 | +646.27% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $36 | $7.67 | +369.36% | 4 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $1.64 | +572.78% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $4.72 | +175.72% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $13 | $5.16 | +151.94% | 4 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 | $23.60 | +213.56% | 7 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $2.40 | +233.33% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $7 | $1.51 | +363.58% | 8 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $3 → $8 | $2.32 | +244.83% | 9 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $0.38 | +1,999.74% | 7 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $52 | $9.27 | +460.95% | 5 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2 → $4 | $3.43 | +16.62% | 4 | May 19, 2020 |
Kura Oncology
Jun 20, 2025
Reiterates: Outperform
Price Target: $36
Current: $5.85
Upside: +515.38%
Zentalis Pharmaceuticals
May 15, 2025
Reiterates: Neutral
Price Target: $4
Current: $1.30
Upside: +208.88%
Werewolf Therapeutics
May 9, 2025
Maintains: Outperform
Price Target: $8 → $6
Current: $1.19
Upside: +404.20%
Revolution Medicines
Apr 28, 2025
Reiterates: Outperform
Price Target: $67
Current: $39.66
Upside: +68.94%
Monte Rosa Therapeutics
Mar 21, 2025
Maintains: Outperform
Price Target: $15 → $17
Current: $4.63
Upside: +267.17%
Arvinas
Mar 12, 2025
Downgrades: Neutral
Price Target: $57 → $12
Current: $7.44
Upside: +61.29%
Day One Biopharmaceuticals
Feb 26, 2025
Reiterates: Outperform
Price Target: $32
Current: $6.32
Upside: +406.33%
IDEAYA Biosciences
Dec 17, 2024
Reiterates: Outperform
Price Target: $52
Current: $21.69
Upside: +139.74%
Tyra Biosciences
Oct 25, 2024
Reiterates: Outperform
Price Target: $28
Current: $9.23
Upside: +203.36%
Black Diamond Therapeutics
Oct 8, 2024
Reiterates: Outperform
Price Target: $16
Current: $2.33
Upside: +586.70%
Oct 3, 2024
Reiterates: Outperform
Price Target: $30
Current: $8.62
Upside: +248.03%
Oct 1, 2024
Maintains: Outperform
Price Target: $25 → $22
Current: $1.17
Upside: +1,780.34%
Sep 20, 2024
Maintains: Outperform
Price Target: $85 → $51
Current: $8.24
Upside: +518.93%
Sep 20, 2024
Reiterates: Outperform
Price Target: $5
Current: $0.67
Upside: +646.27%
Sep 18, 2024
Reiterates: Outperform
Price Target: $36
Current: $7.67
Upside: +369.36%
Aug 13, 2024
Reiterates: Outperform
Price Target: $11
Current: $1.64
Upside: +572.78%
Aug 9, 2024
Reiterates: Outperform
Price Target: $13
Current: $4.72
Upside: +175.72%
Aug 8, 2024
Maintains: Outperform
Price Target: $11 → $13
Current: $5.16
Upside: +151.94%
Aug 8, 2024
Reiterates: Outperform
Price Target: $74
Current: $23.60
Upside: +213.56%
Aug 7, 2024
Reiterates: Outperform
Price Target: $8
Current: $2.40
Upside: +233.33%
Jun 7, 2024
Reiterates: Outperform
Price Target: $7
Current: $1.51
Upside: +363.58%
May 9, 2024
Upgrades: Outperform
Price Target: $3 → $8
Current: $2.32
Upside: +244.83%
May 3, 2024
Reiterates: Outperform
Price Target: $8
Current: $0.38
Upside: +1,999.74%
Nov 8, 2023
Reiterates: Outperform
Price Target: $52
Current: $9.27
Upside: +460.95%
May 19, 2020
Upgrades: Outperform
Price Target: $2 → $4
Current: $3.43
Upside: +16.62%